{"id":46228,"date":"2025-11-10T21:59:35","date_gmt":"2025-11-10T13:59:35","guid":{"rendered":"https:\/\/flcube.com\/?p=46228"},"modified":"2025-11-10T21:59:37","modified_gmt":"2025-11-10T13:59:37","slug":"jiangsu-hengrui-pharmaceuticals-announces-hrs%e2%80%912430-injection-approval-for-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46228","title":{"rendered":"Jiangsu Hengrui Pharmaceuticals Announces HRS\u20112430 Injection Approval for Clinical Trials"},"content":{"rendered":"\n<p>China\u2011listed <strong>Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced today that its novel intravenous anesthetic, <strong>HRS\u20112430 injection<\/strong>, has received approval from the <strong>National Medical Products Administration (NMPA)<\/strong> to commence clinical trials. The drug is specifically designed for induction and maintenance of general anesthesia, as well as sedation and anesthesia for non\u2011intubated surgical procedures.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-product-overview\">Product Overview<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Indication<\/strong><\/td><td>Induction &amp; maintenance of general anesthesia; sedation for non\u2011intubated surgeries<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Intravenous (IV) injection<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Existing IV anesthetics include <strong>Etomidate<\/strong>, <strong>Midazolam<\/strong>, and <strong>Remimazolam<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><em>Clinical trials will evaluate safety, pharmacokinetics, and efficacy relative to established products.<\/em><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-nmpa-approval-milestone\">NMPA Approval Milestone<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Scope of approval<\/strong> \u2013 NMPA has granted a waiver allowing HRS\u20112430 to enter phase\u2011I\/II clinical studies.<\/li>\n\n\n\n<li><strong>Regulatory significance<\/strong> \u2013 The approval positions Hengrui at the forefront of next\u2011generation anesthetic solutions, potentially accelerating time\u2011to\u2011market for a product that could offer improved safety profiles and reduced side effects.<\/li>\n\n\n\n<li><strong>Strategic impact<\/strong> \u2013 A successful trial could augment Hengrui\u2019s anesthetic portfolio, strengthening its market presence in both domestic and international arenas.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Initiate Phase\u2011I trials<\/strong> in selected clinical sites across China.<\/li>\n\n\n\n<li><strong>Data collection<\/strong> to assess pharmacodynamics, pharmacokinetics, and safety endpoints.<\/li>\n\n\n\n<li><strong>Engage with global partners<\/strong> for potential expansion beyond China following positive trial outcomes.<\/li>\n<\/ol>\n\n\n\n<p><strong>About Jiangsu\u202fHengrui\u202fPharmaceuticals<\/strong><br>Founded in 2002, Jiangsu\u202fHengrui is a leading oncology and generics manufacturer in China. With a growing pipeline of innovative therapeutics, the company has become a key player among Chinese A\u2011share companies and enjoys dual listings on Shanghai and Hong Kong exchanges.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements regarding the anticipated clinical outcomes, regulatory submissions, and commercial prospects of HRS\u20112430. These statements are subject to risks and uncertainties that could cause actual results to differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025110701338_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025110701338_c.\"><\/object><a id=\"wp-block-file--media-94390173-ba67-414d-8c0d-46f49b54747a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025110701338_c.pdf\">2025110701338_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025110701338_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-94390173-ba67-414d-8c0d-46f49b54747a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011listed Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd. (SHA: 600276, HKG: 1276) announced today that its novel intravenous&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46230,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,2586,4228,852],"class_list":["post-46228","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiangsu Hengrui Pharmaceuticals Announces HRS\u20112430 Injection Approval for Clinical Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011listed Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd. (SHA: 600276, HKG: 1276) announced today that its novel intravenous anesthetic, HRS\u20112430 injection, has received approval from the National Medical Products Administration (NMPA) to commence clinical trials. The drug is specifically designed for induction and maintenance of general anesthesia, as well as sedation and anesthesia for non\u2011intubated surgical procedures.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46228\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Hengrui Pharmaceuticals Announces HRS\u20112430 Injection Approval for Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"China\u2011listed Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd. (SHA: 600276, HKG: 1276) announced today that its novel intravenous anesthetic, HRS\u20112430 injection, has received approval from the National Medical Products Administration (NMPA) to commence clinical trials. The drug is specifically designed for induction and maintenance of general anesthesia, as well as sedation and anesthesia for non\u2011intubated surgical procedures.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46228\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-10T13:59:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-10T13:59:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1002-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46228#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46228\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Hengrui Pharmaceuticals Announces HRS\u20112430 Injection Approval for Clinical Trials\",\"datePublished\":\"2025-11-10T13:59:35+00:00\",\"dateModified\":\"2025-11-10T13:59:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46228\"},\"wordCount\":303,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46228#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1002-1.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46228#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46228\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46228\",\"name\":\"Jiangsu Hengrui Pharmaceuticals Announces HRS\u20112430 Injection Approval for Clinical Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46228#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46228#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1002-1.webp\",\"datePublished\":\"2025-11-10T13:59:35+00:00\",\"dateModified\":\"2025-11-10T13:59:37+00:00\",\"description\":\"China\u2011listed Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd. (SHA: 600276, HKG: 1276) announced today that its novel intravenous anesthetic, HRS\u20112430 injection, has received approval from the National Medical Products Administration (NMPA) to commence clinical trials. The drug is specifically designed for induction and maintenance of general anesthesia, as well as sedation and anesthesia for non\u2011intubated surgical procedures.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46228#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46228\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46228#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1002-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1002-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jiangsu\u202fHengrui\u202fPharmaceuticals Announces **HRS\u20112430 Injection** Approval for Clinical Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46228#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Hengrui Pharmaceuticals Announces HRS\u20112430 Injection Approval for Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Hengrui Pharmaceuticals Announces HRS\u20112430 Injection Approval for Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011listed Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd. (SHA: 600276, HKG: 1276) announced today that its novel intravenous anesthetic, HRS\u20112430 injection, has received approval from the National Medical Products Administration (NMPA) to commence clinical trials. The drug is specifically designed for induction and maintenance of general anesthesia, as well as sedation and anesthesia for non\u2011intubated surgical procedures.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46228","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Hengrui Pharmaceuticals Announces HRS\u20112430 Injection Approval for Clinical Trials","og_description":"China\u2011listed Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd. (SHA: 600276, HKG: 1276) announced today that its novel intravenous anesthetic, HRS\u20112430 injection, has received approval from the National Medical Products Administration (NMPA) to commence clinical trials. The drug is specifically designed for induction and maintenance of general anesthesia, as well as sedation and anesthesia for non\u2011intubated surgical procedures.","og_url":"https:\/\/flcube.com\/?p=46228","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-10T13:59:35+00:00","article_modified_time":"2025-11-10T13:59:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1002-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46228#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46228"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Hengrui Pharmaceuticals Announces HRS\u20112430 Injection Approval for Clinical Trials","datePublished":"2025-11-10T13:59:35+00:00","dateModified":"2025-11-10T13:59:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46228"},"wordCount":303,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46228#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1002-1.webp","keywords":["Clinical trial approval \/ initiation","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46228#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46228","url":"https:\/\/flcube.com\/?p=46228","name":"Jiangsu Hengrui Pharmaceuticals Announces HRS\u20112430 Injection Approval for Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46228#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46228#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1002-1.webp","datePublished":"2025-11-10T13:59:35+00:00","dateModified":"2025-11-10T13:59:37+00:00","description":"China\u2011listed Jiangsu Hengrui Pharmaceuticals Co.,\u202fLtd. (SHA: 600276, HKG: 1276) announced today that its novel intravenous anesthetic, HRS\u20112430 injection, has received approval from the National Medical Products Administration (NMPA) to commence clinical trials. The drug is specifically designed for induction and maintenance of general anesthesia, as well as sedation and anesthesia for non\u2011intubated surgical procedures.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46228#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46228"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46228#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1002-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1002-1.webp","width":1080,"height":608,"caption":"Jiangsu\u202fHengrui\u202fPharmaceuticals Announces **HRS\u20112430 Injection** Approval for Clinical Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46228#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Hengrui Pharmaceuticals Announces HRS\u20112430 Injection Approval for Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1002-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46228"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46228\/revisions"}],"predecessor-version":[{"id":46231,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46228\/revisions\/46231"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46230"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}